about
The basal transcription machinery as a target for cancer therapyP-TEFb goes viralNew directions for drug-resistant breast cancer: the CDK4/6 inhibitorsTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsMutants of protein kinase A that mimic the ATP-binding site of Aurora kinaseCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsFragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 InhibitorsFascaplysin as a specific inhibitor for CDK4: insights from molecular modellingIdentification and structural-functional analysis of cyclin-dependent kinases of the cattle tick Rhipicephalus (Boophilus) microplusKnocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicinDisrupting the Rb-Raf-1 interaction: a potential therapeutic target for cancer.Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets.Analysis and verification of the HMGB1 signaling pathway.A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBMChk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.CDKs as therapeutic targets for the human genetic disease tuberous sclerosis?Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy, and prevention.ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice.Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stressCyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells.Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2Killing cells by targeting mitosisMYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibitionIdentification of genes associated with laryngeal squamous cell carcinoma samples based on bioinformatic analysis.Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways.Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.Antitumor activity of cell-permeable p18(INK4c) with enhanced membrane and tissue penetration.Structural prediction of the interaction of the tumor suppressor p27KIP1 with cyclin A/CDK2 identifies a novel catalytically relevant determinantA novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.Cyclin-dependent kinase 4 signaling acts as a molecular switch between syngenic differentiation and neural transdifferentiation in human mesenchymal stem cells.New combination therapies with cell-cycle agentsSerum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.Harnessing synthetic lethal interactions in anticancer drug discovery
P2860
Q21246017-FF88F550-5048-47CD-8158-F53A40BD61EFQ26741360-1187427A-F8EC-42C0-AE1A-C3E8B849F0AAQ26797396-DA7BB2F4-A241-4EC8-96FE-94C13F4F5E59Q26827580-BD470BDC-FC9D-405F-9B8D-C308536F4DD0Q27670889-0163B64A-A6DF-4BC3-BAF2-7BD9221B3573Q27670943-5FB642E6-8EFA-4EF0-A56B-954B038C9095Q27684150-06C0049B-20DB-4FAE-8644-B315BD29EC86Q28482234-098849B7-BE98-423D-9574-CB9965FE6948Q28534360-6B792C54-116D-47C9-9965-3C8B01146A48Q33494037-5CE05AE9-9896-4326-B102-D2B2C7719E78Q33566343-142FF1BD-F3DA-4970-BDAD-973E877CC855Q33598661-287A6004-2311-4C3B-8948-868ADA87BC2DQ33755561-CD43D3A3-86CE-4211-9F2B-C464B284B20FQ33786955-112E291E-710F-44D8-8986-458F4CC1C8E9Q33864755-40A18515-FC14-4F88-A5A7-22A4D5822BEDQ33952887-6DF110E5-556A-4A6F-8D7F-8B67447938E3Q34028486-E6D034A4-5877-4698-8AA4-07F9B7F7A67DQ34195072-C2BC50FA-7B3C-43C8-BC64-EAFAE1F6C58AQ34659106-7CA64365-0359-4EAA-AADB-8C45C98A65BCQ34679234-594D68E6-44FD-4993-B0C6-F05AC2A70EBEQ34756557-551D4C3E-CDC1-4D6F-A316-CCD764460880Q34997857-9B1F0605-4CEB-4265-832D-EE4A374EC507Q35011009-6E0CAB07-5672-43D5-9F81-E40742FAAF1EQ35176113-6996F974-EC8F-4957-82E1-218E346B049AQ35236033-F5F3E1DE-A1E4-4B58-A1E5-C6F8225BBAB5Q35661029-46C0702B-5304-436E-B1EA-157E4F64143AQ35722786-8F9424BF-AA6C-44F5-B661-F8F1771552E5Q35754713-49261AC7-E1ED-46BB-B910-AEF9C99C5C74Q35894198-919B3707-3D08-4077-A76E-796AE3B96693Q35919835-EB1427D2-37D9-4817-BEEE-08D40DC2BEE0Q35921803-56AE3634-FA97-4ABC-8DCB-4536E6BC220FQ36141851-338C3323-036E-45B4-8858-E0ACB2E7F7EDQ36142453-C51ADDA0-78AA-4786-949D-4DEA3D35992FQ36240680-CC04EA31-4D7B-4076-9D73-6773A503AE7AQ36326335-ED964476-A5C2-4794-9481-A781BF8D1B45Q36654383-23F74DAC-08F0-437B-9B5F-AA7566C368D7Q36737314-B95DB50E-C292-4E9D-9F62-2CA59C6EFDF5Q36738991-CDFB5F33-36BC-4964-8C93-69AA014AB094Q36769047-D996FEE3-6EEF-4654-9BEE-9F14F03CF8BFQ36839571-B4FE3EC1-E2A3-45D1-B34C-0400C8B4DD39
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
CDK inhibitors in cancer therapy: what is next?
@ast
CDK inhibitors in cancer therapy: what is next?
@en
CDK inhibitors in cancer therapy: what is next?
@nl
type
label
CDK inhibitors in cancer therapy: what is next?
@ast
CDK inhibitors in cancer therapy: what is next?
@en
CDK inhibitors in cancer therapy: what is next?
@nl
prefLabel
CDK inhibitors in cancer therapy: what is next?
@ast
CDK inhibitors in cancer therapy: what is next?
@en
CDK inhibitors in cancer therapy: what is next?
@nl
P2093
P1476
CDK inhibitors in cancer therapy: what is next?
@en
P2093
James R Bischoff
Mariano Barbacid
Paolo Pevarello
P356
10.1016/J.TIPS.2007.10.012
P577
2007-12-04T00:00:00Z